Investor Relations

Corporate Overview

We are a global medical technology company focused on the development and commercialization of our proprietary Vapotherm high velocity therapy, a tool used to treat patients of all ages suffering from respiratory distress. High velocity therapy delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Our Precision Flow systems, which deliver high velocity therapy, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress in a hospital setting. As of June 30, 2020, more than 2.3 million patients have been treated with our Precision Flow systems, and we have a global installed base of over 22,000 capital units.

Latest News

View all news

Latest Presentation

Latest Events

View All Events

Latest Quarterly Reports

View All Financial Reports